Published in World J Hepatol on June 08, 2015
Individualized Immunosuppressive Protocol of Liver Transplant Recipient Should be Made Based on Splenic Function Status. Chin Med J (Engl) (2016) 0.75
Curing Hepatitis C in Liver Transplant Recipients Is Associated with Changes in Immunosuppressant Use. J Clin Transl Hepatol (2016) 0.75
Advances in the Knowledge about Kidney Decellularization and Repopulation. Front Bioeng Biotechnol (2017) 0.75
HOMOTRANSPLANTATION OF THE LIVER IN HUMANS. Surg Gynecol Obstet (1963) 10.22
THE REVERSAL OF REJECTION IN HUMAN RENAL HOMOGRAFTS WITH SUBSEQUENT DEVELOPMENT OF HOMOGRAFT TOLERANCE. Surg Gynecol Obstet (1963) 8.04
Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med (1998) 3.76
Experience in 1,000 liver transplants under cyclosporine-steroid therapy: a survival report. Transplant Proc (1988) 2.87
Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology (2003) 2.76
A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation--PROTECT. Am J Transplant (2012) 2.24
Weaning of immunosuppression in living donor liver transplant recipients. Transplantation (2001) 2.18
Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: an analysis of the Scientific Registry of Transplant Recipients Database. Liver Transpl (2012) 2.14
Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem Biophys Res Commun (2004) 1.93
Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. Hepatology (2013) 1.93
Pregnancy outcome after liver transplantation: a single-center experience of 71 pregnancies in 45 recipients. Liver Transpl (2006) 1.82
Cellular and molecular mechanisms of liver tolerance. Immunol Rev (2006) 1.70
Trial of complete weaning from immunosuppression for liver transplant recipients: factors predictive of tolerance. Liver Transpl (2013) 1.66
A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation (1999) 1.62
OPTN/SRTR 2012 Annual Data Report: liver. Am J Transplant (2014) 1.59
Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: a multicenter study of 412 patients. World J Gastroenterol (2006) 1.58
De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial. Am J Transplant (2014) 1.57
Limiting hepatitis C virus progression in liver transplant recipients using sirolimus-based immunosuppression. Am J Transplant (2011) 1.56
Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial. Am J Transplant (2012) 1.55
Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study. Am J Transplant (2013) 1.54
HLA compatibility and organ transplant survival. Collaborative Transplant Study. Rev Immunogenet (1999) 1.53
Pregnancy outcomes of liver transplant recipients: a systematic review and meta-analysis. Liver Transpl (2012) 1.52
Comparison between two high-dose methylprednisolone schedules in the treatment of acute hepatic cellular rejection in liver transplant recipients: a controlled clinical trial. Liver Transpl (2002) 1.50
Differential effects of calcineurin inhibitors, tacrolimus and cyclosporin a, on interferon-induced antiviral protein in human hepatocyte cells. Liver Transpl (2008) 1.50
Prolongation of long-term kidney graft survival by a simultaneous liver transplant: the liver does it, and the heart does it too. Transplantation (2002) 1.48
Cyclosporine versus tacrolimus treated liver transplant recipients with chronic hepatitis C: outcomes analysis of the UNOS/OPTN database. Am J Transplant (2011) 1.47
Adult living donor versus deceased donor liver transplantation: a 10-year prospective single center experience. Ann Hepatol (2009) 1.44
Serum sickness following rabbit antithymocyte-globulin induction in a liver transplant recipient: case report and literature review. Liver Transpl (2007) 1.43
Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation (2004) 1.43
Outcome of induction immunosuppression for liver transplantation comparing anti-thymocyte globulin, daclizumab, and corticosteroid. Transpl Int (2011) 1.41
The natural history of recurrent hepatitis C and what influences this. Liver Transpl (2008) 1.38
Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation (2006) 1.37
Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA (2012) 1.33
Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant (2005) 1.33
Thiopurine S-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment; a pharmacogenomic test whose time has come. J Clin Pathol (2010) 1.33
Adult living donor versus deceased donor liver transplantation: a 6-year single center experience. Am J Transplant (2005) 1.31
A retrospective review of liver transplant patients treated with sirolimus from a single center: an analysis of sirolimus-related complications. Transplantation (2004) 1.30
Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst Rev (2006) 1.29
Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis. J Hepatol (2006) 1.27
Mycophenolate mofetil-related gastrointestinal mucosal injury: variable injury patterns, including graft-versus-host disease-like changes. Am J Surg Pathol (2008) 1.23
Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl (2009) 1.22
Defining the outcome of immunosuppression withdrawal after liver transplantation. Hepatology (1998) 1.21
Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther (2012) 1.17
Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology (1995) 1.16
Incidence and severity of acute cellular rejection in recipients undergoing adult living donor or deceased donor liver transplantation. Am J Transplant (2008) 1.13
Patterns of injury in mycophenolate mofetil-related colitis. Transplant Proc (2010) 1.12
Induction immunosuppression. Transplantation (2006) 1.10
The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation. Transpl Int (2006) 1.08
Liver transplantation: the current situation. Semin Liver Dis (2009) 1.07
The combined organ effect: protection against rejection? Ann Surg (2008) 1.07
Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage. Liver Transpl (2004) 1.06
Immune tolerance in liver disease. Hepatology (2014) 1.05
Safety, efficacy, and cost analysis of thymoglobulin induction therapy with intermittent dosing based on CD3+ lymphocyte counts in kidney and kidney-pancreas transplant recipients. Transplantation (2002) 1.03
A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: a report of the United States FK506 Study Group. Transplantation (1998) 1.02
Calcineurin inhibitor nephrotoxicity: a review and perspective of the evidence. Am J Nephrol (2013) 1.02
Long-term treatment of bile duct-ligated rats with rapamycin (sirolimus) significantly attenuates liver fibrosis: analysis of the underlying mechanisms. J Pharmacol Exp Ther (2005) 1.00
Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. J Hepatol (2013) 1.00
Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation. Transplantation (2004) 0.99
Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and meta-analysis. Am J Transplant (2012) 0.99
Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition. Liver Cancer (2012) 0.98
Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials. Transpl Int (2011) 0.98
Sirolimus conversion in liver transplant recipients with renal dysfunction: a prospective, randomized, single-center trial. Transplantation (2007) 0.97
A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl (2011) 0.97
Low risk of renal flares and negative outcomes in women with lupus nephritis conceiving after switching from mycophenolate mofetil to azathioprine. Rheumatology (Oxford) (2013) 0.96
Short-term induction therapy with anti-thymocyte globulin and delayed use of calcineurin inhibitors in orthotopic liver transplantation. Liver Transpl (2007) 0.96
Rabbit antithymocyte globulin (thymoglobulin): a review of its use in the prevention and treatment of acute renal allograft rejection. Drugs (2009) 0.94
Liver transplantation: immunosuppression and oncology. Curr Opin Organ Transplant (2014) 0.94
Rationale of personalized immunosuppressive medication for hepatocellular carcinoma patients after liver transplantation. Liver Transpl (2014) 0.91
Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update. Arch Toxicol (2014) 0.91
The safety and efficacy of a two-dose daclizumab (zenapax) induction therapy in liver transplant recipients. Transplantation (2000) 0.88
Classification and terminology of hepatic allograft rejection: whither bound? Mayo Clin Proc (1989) 0.87
Recurrent HCV after liver transplantation-mechanisms, assessment and therapy. Nat Rev Gastroenterol Hepatol (2014) 0.87
A comprehensive review of immunosuppression used for liver transplantation. J Transplant (2009) 0.86
Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year. Transplantation (2007) 0.85
Posttransplantation lymphoproliferative disorder in kidney and heart transplant recipients receiving thymoglobulin: a systematic review. Transplant Proc (2011) 0.85
Multicentric outcome analysis of sirolimus-based immunosuppression in 252 liver transplant recipients. Transpl Int (2009) 0.85
ATG-Fresenius treatment and low-dose tacrolimus: results of a randomized controlled trial in liver transplantation. Am J Transplant (2010) 0.84
Natural history of hepatitis C following liver transplantation. Curr Opin Infect Dis (2004) 0.84
Basiliximab versus steroids in double therapy immunosuppression in liver transplantation: a prospective randomized clinical trial. Transplantation (2008) 0.84
Malignancies after heart transplantation: incidence, risk factors, and effects of calcineurin inhibitor withdrawal. Transplant Proc (2010) 0.84
Switching to sirolimus-based immune suppression after liver transplantation is safe and effective: a single-center experience. Transplantation (2011) 0.84
Combined heart and liver transplantation: a single-center experience. Transplantation (2009) 0.84
Malignancies in 2,753 kidney recipients transplanted during a 39-year experience. Transplant Proc (2009) 0.84
Does the Banff rejection activity index predict outcome in patients with early acute cellular rejection following liver transplantation? Liver Transpl (2006) 0.83
Anti-thymocyte globulin for the treatment of acute cellular rejection following liver transplantation. Dig Dis Sci (2010) 0.83
Calcineurin inhibitors in liver transplantation - still champions or threatened by serious competitors? Liver Int (2013) 0.83
Preliminary results of immunosuppression with thymoglobuline pretreatment and hepatitis C virus recurrence in liver transplantation. Transplant Proc (2005) 0.82
Thymoglobulin-induced severe cardiovascular reaction and acute renal failure in a patient scheduled for orthotopic liver transplantation. Minerva Anestesiol (2006) 0.81
Sirolimus reduces the risk of significant hepatic fibrosis after liver transplantation for hepatitis C virus: a single-center experience. Transplant Proc (2013) 0.81
The effect of HLA mismatches, shared cross-reactive antigen groups, and shared HLA-DR antigens on the outcome after pediatric liver transplantation. Liver Transpl (2005) 0.81
Experience of using everolimus in the early stage of living donor liver transplantation. Transplant Proc (2014) 0.81
Short-term versus long-term induction therapy with antithymocyte globulin in orthotopic liver transplantation. Transpl Int (2007) 0.81
Basiliximab induction in adult liver transplant recipients with 93% rejection-free patient and graft survival at 24 months. Transplant Proc (2006) 0.80
Proteinuria following sirolimus conversion is associated with deterioration of kidney function in liver transplant recipients. Transplantation (2012) 0.80
Corticosteroids usage in pediatric liver transplantation: To be or not to be! Pediatr Transplant (2008) 0.80
C2 monitoring of cyclosporine in de novo liver transplant recipients: the clinician's perspective. Liver Transpl (2004) 0.80
Basiliximab (Simulect) for the treatment of steroid-resistant rejection in pediatric liver transpland recipients: a preliminary experience. Transplantation (2003) 0.79
Incidence, risk factors, and outcome of antithymocyte globulin treatment of steroid-resistant rejection after liver transplantation. Transpl Int (1996) 0.78
Immunosuppression induction with rabbit anti-thymocyte globulin with or without rituximab in 1000 liver transplant patients with long-term follow-up. Liver Transpl (2012) 0.78
Acute sirolimus pulmonary toxicity in an infant heart transplant recipient: case report and literature review. J Heart Lung Transplant (2007) 0.78